Zepbound (Tirzepatide) Constipation Severity Grading: A Clinical Rubric for Patients and Providers
At a glance
- Constipation rate / 17% (5 mg), 14% (10 mg), 11% (15 mg) vs 5% placebo [1]
- Severity breakdown / None given; a single rate per dose [1]
- Severe GI reactions, any / 1.7% (5 mg), 2.5% (10 mg), 3.1% (15 mg) vs 1% [1]
- Labeled caution / Not recommended in severe gastroparesis [1]
- Chronic idiopathic constipation guideline / Strong recommendations include polyethylene glycol, sodium picosulfate, linaclotide, plecanatide and prucalopride [2]
- What NIDDK says doctors ask about / Frequency, duration, stool appearance, blood, diet, activity, medicines [3]
What the label reports
Constipation is one of Zepbound's most common adverse reactions, meaning it occurred in at least 5% of patients [1]. The figures come from two pooled placebo-controlled weight-management trials in which 2,519 adults received Zepbound for up to 72 weeks — 630 received 5 mg, 948 received 10 mg and 941 received 15 mg. Another 958 received placebo [1]. Constipation was reported by 17%, 14% and 11% of the three tirzepatide groups, against 5% on placebo [1].
The pooled rate was highest at 5 mg and lowest at 15 mg [1]. Gastrointestinal adverse reactions led 1.9%, 3.3% and 4.3% of patients to stop treatment, against 0.5% on placebo [1]. The label says most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time; it does not say that about constipation [1].
What the label reports about severe reactions
The label reports severe gastrointestinal reactions as a group — 1.7% at 5 mg, 2.5% at 10 mg, 3.1% at 15 mg, against 1% [1]. Zepbound is not recommended in patients with severe gastroparesis [1].
The label describes acute pancreatitis as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting, and says to discontinue Zepbound if pancreatitis is suspected [1]. It also says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1]. On dosing, it says to consider treatment response and tolerability when choosing a maintenance dose, and a lower maintenance dose if the current one is not tolerated [1].
Laxative evidence is not tirzepatide evidence
The 2023 AGA/ACG guideline made strong recommendations for polyethylene glycol, sodium picosulfate, linaclotide, plecanatide and prucalopride in adults with chronic idiopathic constipation, with conditional recommendations for fiber, lactulose, senna, magnesium oxide and lubiprostone [2]. That guideline covers chronic idiopathic constipation and does not set a regimen for constipation during tirzepatide treatment [2].
Frequently asked questions
How often does constipation occur with Zepbound?
Which symptoms does the Zepbound label treat as serious?
Does constipation get worse at higher doses?
Is polyethylene glycol recommended for constipation on Zepbound?
What does NIDDK say doctors ask about constipation?
References
- U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
- Chang L, Chey WD, Imdad A, Almario CV, Bharucha AE, Diem S, et al. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Am J Gastroenterol. 2023;118(6):936-954. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
- Diagnosis of Constipation - NIDDK. Diagnosis of Constipation - NIDDK